Compare MNTK & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | EDIT |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.2M | 206.0M |
| IPO Year | 2020 | 2016 |
| Metric | MNTK | EDIT |
|---|---|---|
| Price | $1.11 | $2.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.33 | ★ $4.92 |
| AVG Volume (30 Days) | 265.7K | ★ 1.6M |
| Earning Date | 03-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $176,382,000.00 | $31,937,000.00 |
| Revenue This Year | $17.70 | N/A |
| Revenue Next Year | $16.52 | N/A |
| P/E Ratio | $122.80 | ★ N/A |
| Revenue Growth | 0.37 | ★ 132.64 |
| 52 Week Low | $1.18 | $0.91 |
| 52 Week High | $2.78 | $4.54 |
| Indicator | MNTK | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 53.26 |
| Support Level | N/A | $1.84 |
| Resistance Level | $2.07 | $2.36 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.92 | 52.91 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.